Organogenesis Holdings (ORGO) Research & Development (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Research & Development of $15.2 million for Q1 2026, up 42.49% year-over-year from $10.6 million in Q1 2025, and up 47.39% quarter-over-quarter from $10.3 million in Q4 2025.
Organogenesis Holdings (ORGO) Research & Development (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Research & Development history runs 10 years deep, the most recent figure standing at $15.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 42.49% year-over-year to $15.2 million; the TTM figure through Mar 2026 stood at $49.1 million (up 2.0% YoY), while the FY2025 annual figure was $44.5 million, down 11.4% from the prior year.
- Research & Development for Q1 2026 stood at $15.2 million, up from $10.3 million in the prior quarter.
- The five-year high for Research & Development was $15.6 million in Q2 2024, with the low at $8.6 million in Q1 2022.
- The 5-year median for Research & Development is $10.9 million (2023), against an average of $11.4 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 42.5% in 2024, then plunged 33.31% in 2025.
- Organogenesis Holdings' Research & Development stood at $11.4 million in 2022, then increased by 3.29% to $11.8 million in 2023, then decreased by 2.04% to $11.5 million in 2024, then decreased by 10.79% to $10.3 million in 2025, then jumped by 47.39% to $15.2 million in 2026.
- Business Quant data shows ORGO's Research & Development at $15.2 million in Q1 2026, $10.3 million in Q4 2025, and $13.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Organogenesis Holdings | 241.91 Mn | 195.06 Mn | 20.08 Mn | 18.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.30 Mn |
| Mar 31, 2026 | 15.16 Mn |
| Dec 31, 2025 | 10.29 Mn |
| Sep 30, 2025 | 13.22 Mn |
| Jun 30, 2025 | 10.40 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 11.53 Mn |
| Sep 30, 2024 | 10.34 Mn |
| Jun 30, 2024 | 15.59 Mn |
| Mar 31, 2024 | 12.81 Mn |
| Dec 31, 2023 | 11.77 Mn |
| Sep 30, 2023 | 10.47 Mn |
| Jun 30, 2023 | 10.94 Mn |
| Mar 31, 2023 | 11.20 Mn |
| Dec 31, 2022 | 11.40 Mn |
| Sep 30, 2022 | 9.58 Mn |
| Jun 30, 2022 | 10.21 Mn |
| Mar 31, 2022 | 8.59 Mn |
| Dec 31, 2021 | 8.26 Mn |
| Sep 30, 2021 | 8.95 Mn |